Optimi Health Corp. (OPTI.CN)
| Previous close | 0.3550 |
| Open | 0.3650 |
| Bid | 0.3650 x N/A |
| Ask | 0.3750 x N/A |
| Day's range | 0.3650 - 0.3750 |
| 52-week range | 0.1500 - 0.5800 |
| Volume | |
| Avg. volume | 91,877 |
| Market cap | 32.959M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
The Company has also completed the GMP validation work allowing for the release of both MDMA dosage formatsVANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has received a Certificate of Analysis (COA) from independent third-party laboratory testin
- GlobeNewswire
Optimi Health Provides Corporate Update
VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, announces that it intends to close the final tranche of its non-brokered private placement imminently (the “Offering”). The Offering consists of units (each a “Unit”) at CAD$0.30 per Unit for gro
- GlobeNewswire
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international exportVANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to report a significant update to its collaboration with The Institute for Psychedelic Research at T
